MN and IIIB Recombinant Glycoprotein 120 Vaccine-Induced Binding Antibodies to Native Envelope Glycoprotein of Human Immunodeficiency Virus Type 1 Primary Isolates
- 1 July 1999
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 15 (10) , 921-930
- https://doi.org/10.1089/088922299310638
Abstract
The ability of antibody induced by MN and IIIB recombinant gp120 (rgp120) human immunodeficiency virus type 1 (HIV-1) vaccines to bind to oligomeric native HIV-1 envelope glycoproteins of primary isolates of HIV-1 was measured by flow cytometric indirect immunofluorescence assay (FIFA) in 25 uninfected, healthy adults. After three immunizations, MN rgp120 HIV-1 vaccine given alone and coadministered with IIIB rgp120 HIV-1 vaccine elicited antibody that bound to cells infected with each of a panel of six subtype B strains of HIV-1. Lower levels of vaccine-induced binding antibody were detected against envelope subtype A, D, and (EA) strains of HIV-1 than against subtype B strains. Priming immunization with IIIB rgp120 HIV-1 vaccine alone induced low levels of antibody capable of binding to envelope glycoprotein of primary isolate strains of HIV-1, and booster immunizations with MN rgp120 HIV-1 vaccine resulted in much higher antibody levels. We conclude that MN rgp120 HIV-1 vaccine was an effective inducer of antibody to native envelope glycoproteins of antigenically diverse primary isolates of HIV-1.Keywords
This publication has 22 references indexed in Scilit:
- Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing HIV‐1Mngp120, HIV‐1SF2Recombinant gp120, or Both Vaccines in Seronegative AdultsThe Journal of Infectious Diseases, 1998
- Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administrationVaccine, 1998
- Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines.The Journal of Infectious Diseases, 1997
- Immunization with Envelope Subunit Vaccine Products Elicits Neutralizing Antibodies against Laboratory-Adapted but Not Primary Isolates of Human Immunodeficiency Virus Type 1The Journal of Infectious Diseases, 1996
- HIV Type 1 Variation in World Health Organization-Sponsored Vaccine Evaluation Sites: Genetic Screening, Sequence Analysis, and Preliminary Biological Characterization of Selected Viral StrainsAIDS Research and Human Retroviruses, 1994
- Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials NetworkJAMA, 1994
- Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteinsVaccine, 1994
- Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccineThe Lancet, 1993